https://www.selleckchem.com/pr....oducts/k-ras-g12c-in
Preventive interventions are needed to protect residents and staff of skilled nursing and assisted living facilities from COVID-19 during outbreaks in their facilities. Bamlanivimab, a neutralizing monoclonal antibody against SARS-CoV-2, may confer rapid protection from SARS-CoV-2 infection and COVID-19. To determine the effect of bamlanivimab on the incidence of COVID-19 among residents and staff of skilled nursing and assisted living facilities. Randomized, double-blind, single-dose, phase 3 trial that enrolled residents
Like
Comment
Share
